Ok to the vaccine. The good news of the day, among the others that arouse great concern, is there. Ema has given its approval to the vaccine developed by Pfizer-Biontech, paving the way for the green light of the EU a few hours later.
It is the final step to be able to start with the «vaccination days» announced by the President of the Commission, Ursula von der Leyen, set for 27, 28 and 29 December. Brussels has secured hundreds of millions of doses of the various drugs under approval, with the aim of covering the entire EU population by next year.
«Today we add an important chapter to a European success story – said von der Leyen – We have approved the first safe and effective vaccine against Covid-19. More vaccines will arrive soon. The doses of the vaccine approved today will be available for all countries ».
Today we add an important chapter to a European success story, by making available the 1st #COVID19 vaccine for Europeans.
More will come.
It will be available to all EU countries at the same time, on the same conditions #EUvaccinationdays https://t.co/4Xa17PQkMv
– Ursula von der Leyen (@vonderleyen) December 21, 2020
Together with the approval, l‘Ema also reported another important data, linked to the new virus variant which circulates in Great Britain but which by now is already widespread in most of Europe, and that is that “at the moment”there is no evidence to suggest that the new vaccine will not work on the new variety of the coronavirus».
The study to get to the vaccine
The clinical study obtained following the experimentation out of about 44,000 people in total, starting from 16 years of age, explained the EMA, “demonstrated 95% effectiveness“. Effectiveness, he adds, calculated in over 36,000 (including people over 75 years of age) who did not have any signs of previous infection », explains the EMA.
«The side effects of this vaccine are the same as those seen on other vaccines“, Underlined Sabine Straus, president of the EMA safety committee, during the press conference and the most frequent encountered in the experimentation phase are” pain during injection, fatigue, headache, pain in muscles and ligaments, high fever, but they last about a day, ”Straus said.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
